June 2026– date –
-
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Biogen Pivots Post-Apellis Acquisition: Halts Most R&D, Concentrates on Commercial Assets
Endpoints News USA Overview Biogen has confirmed it will suspend or terminate "most" of Apellis Pharmaceuticals' research programs and lay off some employees following its $5.6 billion acquisition. This strategic pivot is part of integra... -
RQ Bio Secures $115M to Fast-Track Long-Acting Antibody RQB01, Revolutionizing Flu Prevention for Vulnerable Patients
GlobeNewswire UK Overview RQ Bio has successfully closed a $115 million (approximately £85.5 million) Series A funding round, led by Frazier Life Sciences, to accelerate the clinical development of RQB01. This long-acting antibody progra... -
MAIA Biotechnology Completes Global Enrollment for Phase 2 Ateganosine Trial in Refractory NSCLC
GlobeNewswire USA Overview MAIA Biotechnology has completed global enrollment for Part C of its Phase 2 THIO-101 expanded trial, evaluating ateganosine for third-line advanced non-small cell lung cancer (NSCLC). Ateganosine, an investiga... -
BMS Reveals Promising Clinical Data for Next-Gen Blood Cancer Therapy Mezigdomide
BioPharma Dive USA Overview Bristol Myers Squibb (BMS) unveiled promising new clinical data for mezigdomide, its next-generation blood cancer therapy. This drug is one of two key protein degradation inducers BMS expects to succeed its mu... -
Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases
BioPharma Dive USA Overview Novartis' RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary en... -
HHS Unveils Strategy to Accelerate US Drug Discovery, Stemming Clinical Trial Shift to China
BioPharma Dive USA Overview The U.S. Department of Health and Human Services (HHS) has launched a comprehensive initiative to accelerate early-stage drug research domestically, directly countering the recent trend of clinical trials migr... -
Major Setback: Pfizer’s Seagen-Acquired ADC Fails Phase 3 in Advanced Lung Cancer
BioPharma Dive USA Overview Pfizer's antibody-drug conjugate (ADC), sigvotatug vedotin, acquired through its Seagen acquisition, failed to meet its primary endpoint of improved overall survival (OS) in a Phase 3 clinical trial for patien... -
Vertex AI-Designed Candidates Hit Phase 1/2 Trials, Accelerating AI-Driven Drug Discovery
Vertex AI Search (PharmaJournalist) USA Overview Multiple AI-designed drug candidates, developed using Vertex AI Search, have advanced to Phase 1 and 2 clinical trials, firmly establishing AI as a pivotal force in pharmaceutical R&D.... -
Breaking the Blood-Brain Barrier: Next-Gen Strategies Unveil Neurological Drug Delivery Innovation
Pharmaceutical Conferences 2026 International会議 Overview A recent conference on June 22, 2026, showcased groundbreaking drug delivery strategies designed to circumvent the formidable blood-brain barrier (BBB). These innovations, includ...
